North Carolina Headlines

Crohn’s disease Pipeline Insight, 2025

Crohn’s Disease Pipeline constitutes 70+ key companies continuously working towards developing 80+ Crohn’s Disease treatment therapies, analyzes DelveInsight.

Crohn’s Disease Overview:

Crohn’s disease (CD) is a type of inflammatory bowel disease (IBD) characterized by chronic, immune-driven inflammation that can affect any part of the gastrointestinal (GI) tract. The inflammation in CD is transmural, meaning it impacts the entire thickness of the bowel wall, from the innermost lining to the outer layer. The disease typically follows a relapsing-remitting course, with periods of symptom flare-ups followed by remission. Over time, repeated inflammation can lead to complications like strictures (narrowing of the bowel) or fistulas (abnormal connections between organs). CD most commonly affects the terminal ileum and right colon, though it may involve the small intestine, colon, or both. Approximately one-third of patients have small bowel-only disease, 20% have colon-only involvement, and about half have both.

The underlying mechanisms of Crohn’s disease are complex and not fully understood, but involve a combination of genetic susceptibility, environmental triggers, microbial factors, and immune system dysfunction. The disease typically begins with inflammation in the intestinal crypts, progressing to ulceration of the mucosal surface and deeper tissues. This chronic inflammation can lead to the formation of non-caseating granulomas—a histological hallmark of CD—and cause the intestinal lining to take on a cobblestone appearance, with alternating inflamed and healthy tissue (“skip lesions”). As inflammation recurs, affected areas may heal with scarring, contributing to long-term structural damage in the intestines. There is currently no cure, and the unpredictable disease course often leads to a reduced quality of life.

Request for a detailed insights report on Crohn’s Disease pipeline insights

“Crohn’s Disease Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Crohn’s Disease Therapeutics Market.

Key Takeaways from the Crohn’s Disease Pipeline Report

• DelveInsight’s Crohn’s Disease pipeline report depicts a robust space with 180+ active players working to develop 200+ pipeline therapies for Crohn’s Disease treatment.

• In October 2023, the FDA granted approval for OMVOH (mirikizumab-mrkz) infusion (300 mg/15 mL) and injection (100 mg/mL), making it the first and only interleukin-23p19 (IL-23p19) antagonist approved for treating moderately to severely active ulcerative colitis (UC) in adults.

• In May 2023, the FDA also approved RINVOQ (upadacitinib) for the treatment of adults with moderately to severely active Crohn’s disease who have not responded adequately or are intolerant to one or more TNF blockers.

• Key Crohn’s Disease companies such as Anssen, RedHill Biopharma, Amgen, Pfizer, Prometheus Biosciences, AgomAb Therapeutics, Hoffmann-La Roche, Gilead Sciences, Eli Lilly and Company, Celgene, AstraZeneca, Mesoblast, Alfasigma, Tiziana Life Sciences, Abivax, Arena Pharmaceuticals, Cytocom, HAV Vaccines Ltd, Enzo Biochem Inc., Stero Biotechs, Reistone Biopharma Company Limited, Qu Biologics, Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceuticals, Soligenix, Immunic, Atlantic Healthcare, 4D Pharma, Landos Biopharma, Janssen, Roche, Eisai, Bristol-Myers Squibb, and others are evaluating new drugs for Crohn’s Disease to improve the treatment landscape.

• Promising Crohn’s Disease pipeline therapies in various stages of development include Ozanimod, Etrasimod, CBP-307, IMU-856, and others.

Crohn’s Disease Pipeline Analysis

The report provides insights into:

• The report provides detailed insights into the key companies that are developing therapies in the Crohn’s Disease Market.

• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Crohn’s Disease treatment.

• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Crohn’s Disease market.

Download our free sample page report on Crohn’s Disease pipeline insights

Crohn’s Disease Emerging Drugs

• Ozanimod: Bristol-Myers Squibb

• Etrasimod: Pfizer

• CBP-307: Suzhou Connect Biopharmaceuticals

• IMU-856: Immunic

Crohn’s Disease Companies

Over 70 leading companies are currently engaged in developing therapies for Crohn’s Disease. Among these, Bristol-Myers Squibb stands out with its drug candidates having reached the most advanced phase of development—Phase III clinical trials.

DelveInsight’s report covers around 200+ products under different phases of clinical development like

• Late stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I) along with the details of

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

Crohn’s Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous

• Subcutaneous

• Oral

• Intramuscular

Crohn’s Disease Products have been categorized under various Molecule types such as

• Monoclonal antibody

• Small molecule

• Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Crohn’s Disease Therapies and Key Companies: Crohn’s Disease Clinical Trials and advancements

Crohn’s Disease Pipeline Therapeutic Assessment

• Crohn’s Disease Assessment by Product Type

• Crohn’s Disease By Stage

• Crohn’s Disease Assessment by Route of Administration

• Crohn’s Disease Assessment by Molecule Type

Download Crohn’s Disease Sample report to know in detail about the Crohn’s Disease treatment market @ Crohn’s Disease Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. Crohn’s Disease Current Treatment Patterns

4. Crohn’s Disease – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Crohn’s Disease Late-Stage Products (Phase-III)

7. Crohn’s Disease Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Crohn’s Disease Discontinued Products

13. Crohn’s Disease Product Profiles

14. Crohn’s Disease Key Companies

15. Crohn’s Disease Key Products

16. Dormant and Discontinued Products

17. Crohn’s Disease Unmet Needs

18. Crohn’s Disease Future Perspectives

19. Crohn’s Disease Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Crohn’s Disease Pipeline Reports Offerings

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/